Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 18/20 | 0.51 |
| ▸ | ITGA4 | P13612 | 18/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL92551 | 0.90 | ITGA4 (0.64) | ITGB1ITGA4 | |
| SCHEMBL93053 | 0.89 | ITGB1 (0.54) | ITGB1ITGA4 | |
| SCHEMBL10273103 | 0.89 | ITGB1 (0.56) | ITGB1ITGA4 | |
| SCHEMBL10273798 | 0.89 | ITGB1 (0.54) | ITGB1ITGA4 | |
| SCHEMBL10273799 | 0.89 | ITGB1 (0.56) | ITGB1ITGA4 | |
| SCHEMBL92356 | 0.89 | ITGB1 (0.56) | ITGB1ITGA4 | |
| SCHEMBL14263706 | 0.85 | ITGB1 (0.67) | ITGB1ITGA4 | |
| SCHEMBL10273039 | 0.85 | ITGB1 (0.56) | ITGB1ITGA4 | |
| SCHEMBL10273028 | 0.84 | ITGB1 (0.65) | ITGB1ITGA4 | |
| SCHEMBL93088 | 0.84 | ITGA4 (0.66) | ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | ITGB1 22/4885ITGA4 3/4885LMNA 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.